Aisling Capital is a leading investment firm that invests in companies developing and commercializing important and innovative healthcare products, services and technologies.

Meet Our Team

A combined 150+ years of experience in the healthcare industry.

learn more

See Our Portfolio

$1.8 billion in assets, with a track record of investing and returning capital since 2000.

learn more

Latest News

Harmony Biosciences Announces File Acceptance Of Its New Drug Application For Pitolisant

February 12, 2019
PLYMOUTH MEETING, Pa., Feb. 12, 2019 /PRNewswire/ -- Harmony Biosciences, LLC (Harmony) announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for its…

BridgeBio Pharma Closes $299.2 Million Financing Round to Support Its Efforts to Target Genetic Disease at the Source

January 26, 2019
PALO ALTO, Calif.--(BUSINESS WIRE)--BridgeBio Pharma, a clinical-stage biopharmaceutical company focused on genetic diseases, today announced a new financing round of $299.2 million. The round was co-led by existing investors KKR…

TransEnterix Receives FDA 510(k) Clearance for Senhance Ultrasonic System

January 15, 2019
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Jan. 15, 2019-- TransEnterix, Inc. (NYSE American:TRXC), a medical device company that is digitizing the interface between surgeons and patients to improve minimally invasive surgery, today…